What is Radiopharm Theranostics?
Radiopharm Theranostics operates as a specialized clinical-stage biotechnology entity focused on the intersection of molecular biology and nuclear medicine. The company develops a robust pipeline of radiopharmaceuticals designed to enhance the precision of cancer detection and therapeutic delivery. By integrating targeted molecules with advanced radioisotopes, the firm provides clinicians with sophisticated tools to monitor disease progression and administer localized treatments. This dual-action approach—combining diagnostic accuracy with therapeutic efficacy—positions the company as a key player in the precision oncology market, where the demand for targeted, patient-specific interventions continues to rise.
How much funding has Radiopharm Theranostics raised?
Radiopharm Theranostics has raised a total of $78.8M across 2 funding rounds:
Private Equity
$70M
Stock/Share Issuance
$8.8M
Private Equity (2024): $70M with participation from Lantheus
Stock/Share Issuance (2026): $8.9M, investors not publicly disclosed
Key Investors in Radiopharm Theranostics
Lantheus
Lantheus is a healthcare technology company specializing in medical imaging, diagnostics, and targeted therapeutics, with a focus on empowering clinicians to identify and monitor complex diseases.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Radiopharm Theranostics?
With the recent influx of capital, Radiopharm Theranostics is strategically positioned to scale its clinical trial operations and deepen its research into novel radioisotope applications. The company's roadmap emphasizes the transition of its lead candidates through late-stage development, aiming to secure regulatory milestones that will validate its therapeutic platform. Future growth will likely be driven by strategic partnerships and the continued refinement of its diagnostic-therapeutic, or theranostic, product suite. As the firm matures, its ability to navigate the complex regulatory environment while maintaining a high-velocity R&D cycle will be paramount to its long-term market leadership in the biotechnology sector.
See full Radiopharm Theranostics company page
